UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Certain bonds and fund structures minimize tax impact, making them attractive for retirees seeking reliable after-tax income.
22,683 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Analysts trimmed Home Depot price targets after the retailer's Q1 results, signaling a cyclical pause rather than a l...
BingEx reports Q1 2026 results that reveal both momentum and headwinds. This article breaks down the key numbers, exp...
D-Wave Quantum stock is rallying on recent funding news and government support. This guide breaks down what that mean...
Bitcoin sits at a pivotal crossroads as on-chain and technical indicators converge around the $70K realized price ban...
Agora's API-driven platform powers live video, voice, and real-time engagement for apps worldwide. This deep dive exa...
Visa and Mastercard dominate the way billions of purchases are paid for worldwide. This article explains why their ne...
As Bank Montreal prepares to report its Q2 2026 results, investors want clarity on growth, credit quality, and return...
Marvell Technology recently reached a new high, prompting questions about its staying power. This guide breaks down t...
Investors are watching Bionano Genomics as the company enters 2026 with evolving demand for optical genome mapping. T...
Remax Premier Realty credits a laser-focused agent-recruitment program for surging growth from 2021-2025, culminating...
When a high-profile IPO opens its doors to everyday traders, the landscape for retail investors changes. This guide e...